Study focus area



Our implementation research projects have a global reach and focus on improving the HIV prevention and care continuum.

We are dedicated to identifying strategies to bridge the gap between the availability of effective HIV medications and the access and use of those medicines to better the lives of people living with HIV and of individuals seeking HIV prevention options.

  • Health-Related Quality of Life.

    Our implementation research projects focus on improving health-related quality of life for people living with and ageing with HIV. We are committed to better measurement of health-quality of life, improving the mental health and well-being of people living with and ageing with HIV, leveraging technology to deliver high quality HIV care, and ensuring the voices of people living with HIV are heard.

  • Adherence & Retention in Care

    We are committed to improving the HIV treatment cascade by preventing loss to follow up, encouraging adherence, and improving access to HIV services and medications. Our implementation research projects focus on diagnosing new patients, ensuring medical appointments are kept, encouraging people living with HIV to take their HIV medicines as prescribed, and overcoming barriers and enable people living with HIV to access care and treatment, by overcoming the barriers they face.

  • Stigma & Discrimination

    High rates of HIV-related stigma and discrimination persist despite considerable efforts to combat it. Our implementation research projects focus on spreading the U=U message and HIV awareness and education. We are committed to eliminating stigma and discrimination, which deter health-seeking behaviour and severely impact health related quality of life for people living with HIV.

  • Ageing

    Although people living with HIV who can access medicines can now have similar life expectancies as those without HIV, patients ageing with HIV often self-report high levels of loneliness and are more likely to have depression, anxiety, and low quality of life compared to individuals living without HIV. Our implementation research projects are dedicated to improving quality of life for ageing patients to help patients age with dignity.

  • Paediatrics

    Ending paediatric HIV is an urgent global health priority. Our implementation science research projects focus on overcoming several barriers, including missed opportunities to test pregnant women for HIV and testing children at birth, poor linkage to care, lower retention in care, and viral load suppression challenges. We are committed to supporting implementation research focused on closing gaps that are preventing the end of paediatric AIDS.

  • Long-Acting Treatment Implementation.

    The development of long-acting HIV treatment medications for HIV and effective implementation will be critical to ensuring optimal access and uptake to those that need them. Our studies are dedicated to finding the best strategies to support successful implementation of long-acting HIV treatment in people living with HIV who may benefit.

Our partnerships

Our partnerships

We are proud to partner with multiple organizations that work to prevent HIV and improve the lives of people who live with HIV.

Find out more

NP-GBL-HVU-WCNT-220005 | March 2022

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.